A detailed history of Geode Capital Management, LLC transactions in Cv Rx, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 288,681 shares of CVRX stock, worth $4.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
288,681
Previous 256,130 12.71%
Holding current value
$4.45 Million
Previous $4.66 Million 25.79%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$6.49 - $19.2 $211,255 - $624,979
32,551 Added 12.71%
288,681 $3.46 Million
Q1 2024

May 13, 2024

BUY
$17.99 - $30.49 $118,500 - $200,837
6,587 Added 2.64%
256,130 $4.66 Million
Q4 2023

Feb 13, 2024

BUY
$11.67 - $33.01 $157,661 - $445,965
13,510 Added 5.72%
249,543 $7.85 Million
Q3 2023

Nov 13, 2023

BUY
$13.56 - $18.47 $96,425 - $131,340
7,111 Added 3.11%
236,033 $3.58 Million
Q2 2023

Aug 11, 2023

BUY
$8.57 - $15.44 $989,517 - $1.78 Million
115,463 Added 101.77%
228,922 $3.53 Million
Q1 2023

May 15, 2023

BUY
$7.08 - $19.4 $34,040 - $93,275
4,808 Added 4.43%
113,459 $1.06 Million
Q4 2022

Feb 13, 2023

BUY
$8.94 - $18.35 $47,739 - $97,989
5,340 Added 5.17%
108,651 $1.99 Million
Q3 2022

Nov 14, 2022

BUY
$6.12 - $9.5 $238,043 - $369,512
38,896 Added 60.38%
103,311 $963,000
Q2 2022

Aug 12, 2022

SELL
$4.7 - $7.22 $450,523 - $692,080
-95,856 Reduced 59.81%
64,415 $387,000
Q1 2022

May 13, 2022

BUY
$5.62 - $12.37 $194,480 - $428,063
34,605 Added 27.54%
160,271 $960,000
Q4 2021

Feb 11, 2022

BUY
$10.65 - $18.61 $493,031 - $861,531
46,294 Added 58.33%
125,666 $1.54 Million
Q3 2021

Nov 12, 2021

BUY
$14.65 - $26.07 $1.16 Million - $2.07 Million
79,372 New
79,372 $1.31 Million

Others Institutions Holding CVRX

About CVRx, Inc.


  • Ticker CVRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,576,200
  • Market Cap $317M
  • Description
  • CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...
More about CVRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.